Sociedad Americana de Hirudoterapia

Identifying factors affecting outcomes in scalp replantation: a systematic review of the literature

Systematic review published in J Reconstr Microsurg (2021)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Systematic reviewEnsayos clínicosKotamarti VS et al. · Journal of reconstructive microsurgery, 2021

Abstract

BACKGROUND:  Replantation is the ideal treatment in traumatic scalp defects to provide immediate coverage with restoration of hair-bearing skin. However, data are limited to case reports and small case series. Comprehensive analysis of techniques and outcomes is not available. Our aim was to systematically analyze the available literature to better understand management and postoperative outcomes of patients undergoing scalp replantation. METHODS:  A systematic review of the PubMed, Cochrane, and EBSCO databases was performed in October 2019. Search terms included "replantation," "replant," "revascularized," "revascularization," "avulsion," and "scalp." Only papers reporting microvascular replantation of completely avulsed scalps, including case reports, were included. Review articles, non-English language articles, articles discussing nonreplant coverage, incomplete scalp avulsions, and articles discussing delayed scalp replantation were excluded. Data extracted included demographics, percent of scalp affected, mechanism, operative technique, and postoperative outcomes. Statistical analysis was performed using Mann-Whitney U tests, Kruskal-Wallis, and chi-squared tests. RESULTS:  From a total of 704 initial results, 61 studies were included for analysis comprising 149 scalps. Complete survival was achieved in 54.7%, partial survival in 38.9%, and failure in 6.7%. Total ischemia time greater than 12 hours was associated with complete replant failure. Arterial anastomoses appeared to protect against complete loss. The number of venous repairs, proportion of venous-to-arterial repairs, use of vein grafts, thromboprophylaxis, or intraoperative complications did not affect outcomes. Patients required significant volumes of blood products, which was associated with partial success. Salvage rate after unplanned return to the operating room was 60.0%. Normal hair growth was achieved in all surviving native scalp tissue. CONCLUSION:  Scalp replantations, while technically challenging, are the ideal treatment for scalp avulsions. Fortunately, these have high rates of success. And as a focal point of a patient's appearance, this is invaluable in restoration of a sense of normalcy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleSystematic Review
Indexed MeSH termsAnticoagulantsHumansMicrosurgeryReplantationScalpVenous Thromboembolism

Resumen

Systematic review of 149 scalp replantation cases finding 54.7% complete survival, 38.9% partial survival, 6.7% failure. Total ischemia time >12h associated with failure.

Por qué esto importa para la hirudoterapia

This systematic review analyzed 61 studies comprising 149 microvascular scalp replantation cases, reporting a 54.7% complete survival rate and identifying total ischemia time over 12 hours as associated with complete replant failure. The study makes no mention of leech therapy or hirudotherapy. While scalp replantation can involve venous congestion management—a setting where medicinal leeches are sometimes used adjunctively—this review does not address that aspect, and the number of venous repairs or thromboprophylaxis did not significantly affect outcomes. Relevance to ASH's domain is indirect at best, limited to the broader surgical context of tissue replantation. No leeches were involved in any reported aspect.

Citación

Identifying factors affecting outcomes in scalp replantation: a systematic review of the literature.

Kotamarti VS et al. · Journal of reconstructive microsurgery, 2021

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.